...
首页> 外文期刊>Methods and findings in experimental and clinical pharmacology >Renin-angiotensin-aldosterone system gene polymorphisms and antihypertensive response to irbesartan in Chinese hypertensives.
【24h】

Renin-angiotensin-aldosterone system gene polymorphisms and antihypertensive response to irbesartan in Chinese hypertensives.

机译:肾素-血管紧张素-醛固酮系统基因多态性与中国高血压患者对厄贝沙坦的降压反应。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to determine whether specific single nucleotide polymorphisms (SNPs) and their reconstructed haplotypes in renin-angiotensin-aldosterone system (RAAS) genes were associated with antihypertensive reduction to irbesartan treatment. Thousand one forty-two hypertensives were recruited and received 150 mg irbesartan daily for 4 weeks. Blood pressures (BPs) and blood samples, at postdose on the 28th day, were measured. Predose BPs and plasma irbesartan concentrations were also measured. Involved SNPs in RAAS pathway genes were genotyped. Genotype (-344 TC) in the CYP11B2 had a significantly greater systolic blood pressure (SBP) reduction versus the TT genotype (p = 0.001). Subjects with the 174MM genotype of the angiotensinogen (AGT) gene had a significantly greater average SBP reduction (p = 0.025). The C-344T and T1016C polymorphisms in the CYP11B2 gene were both significantly associated with diastolic blood pressure (DBP) reduction (p = 0.026 or p = 0.003). Overall, the three loci-constructed haplotypes of the CYP11B2 gene were associated with DBP reduction (p = 0.008). Haplo-GLM analyses demonstrated that subjects with haplotype CTA had a significantly greater SBP and DBP reductions (p < 0.001 or p = 0.020), whereas subjects with haplotype TAA had a significantly lower SBP and DBP reductions (p < 0.001). Our findings suggested that SNPs and their reconstructed haplotypes in RAAS genes might be involved in the regulation of BP-lowering response to irbesartan in Chinese hypertensives.
机译:这项研究的目的是确定是否在肾素-血管紧张素-醛固酮系统(RAAS)基因中特定的单核苷酸多态性(SNPs)及其重构的单倍型与降压治疗厄贝沙坦有关。招募了142名高血压患者,每天接受150 mg厄贝沙坦治疗4周。在服药后第28天测量血压(BPs)和血液样本。还测量了给药前的血压和血浆厄贝沙坦浓度。对RAAS途径基因中涉及的SNP进行基因分型。与TT基因型相比,CYP11B2中的基因型(-344 TC)的收缩压降低(SBP)明显更大。(p = 0.001)血管紧张素原(AGT)基因为174MM基因型的受试者的平均SBP降低显着更大(p = 0.025)。 CYP11B2基因的C-344T和T1016C多态性均与舒张压(DBP)降低显着相关(p = 0.026或p = 0.003)。总体而言,CYP11B2基因的三个基因座构建的单倍型与DBP降低相关(p = 0.008)。 Haplo-GLM分析表明,单倍型CTA的受试者的SBP和DBP降低明显更高(p <0.001或p = 0.020),而单倍型TAA的受试者的SBP和DBP降低明显更低(p <0.001)。我们的发现表明,RAAS基因中的SNP及其重构的单倍型可能参与了中国高血压患者对厄贝沙坦的BP降低反应的调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号